RCKT on Nasdaq

Rocket Pharmaceuticals Inc.

Biopharmaceutical company.¹

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerRCKT on Nasdaq¹
Industrypharmaceutical industry¹
HeadquartersCranbury¹
Websiterocketpharma.com
Incorporated inDE³
Business address350 Fifth Avenue, Suite 7530, New York, Ny 10118³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-80.5%Return on equity⁴

-$190.5MFree cash flow⁴

Financial statements

Revenue⁵⁶⁷⁸⁴$0 in 2025

Operating income⁵⁶⁷⁸⁴-$231.7M in 2025+204% since 2019

Net income⁵⁶⁷⁸⁴-$223.1M in 2025+189% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Revenue	$0	$0
Research and development	$142.0M	$171.2M
General and administrative	$86.5M	$102.0M
Restructuring	$3.2M	$0
Total operating expenses	$231.7M	$273.2M
Loss from operations	-$231.7M	-$273.2M
Interest expense	-$1.9M	-$1.9M
Interest and other income, net	$3.2M	$8.3M
Accretion of discount on investments, net	$7.3M	$8.1M
Net loss	-$223.1M	-$258.7M
Net loss per share - basic (in dollars per share)	-$2.01	-$2.73
Net loss per share - diluted (in dollars per share)	-$2.01	-$2.73
Weighted-average common shares outstanding - basic (in shares)	111.1M shares	94.8M shares
Weighted-average common shares outstanding - diluted (in shares)	111.1M shares	94.8M shares

Total assets¹¹⁵⁶⁷⁸⁴$330.4M in 2025−11% since 2019

Total liabilities¹¹⁵⁶⁷⁸⁴$53.2M in 2025−18% since 2019

Shareholders’ equity⁶⁷⁸⁴$277.2M in 2025−10% since 2019

Cash¹¹⁵⁶⁷⁸⁴$77.6M in 2025−58% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$77.6M	$163.6M
Investments	$111.4M	$208.7M
Prepaid expenses and other current assets	$3.8M	$5.8M
Total current assets	$192.7M	$378.2M
Property and equipment, net	$28.2M	$36.8M
Goodwill	$39.2M	$39.2M
Intangible assets	$25.1M	$25.1M
Restricted cash	$1.3M	$1.4M
Deposits	$482.0K	$529.0K
Operating lease right-of-use assets, net	$3.2M	$4.2M
Finance lease right-of-use asset, net	$40.2M	$42.4M
Total assets	$330.4M	$527.7M
Accounts payable and accrued expenses	$27.3M	$37.8M
Operating lease liabilities, current	$1.0M	$1.0M
Finance lease liability, current	$1.9M	$1.9M
Total current liabilities	$30.2M	$40.7M
Operating lease liabilities, non-current	$2.6M	$3.3M
Finance lease liability, non-current	$19.4M	$19.4M
Other liabilities	$1.1M	$1.1M
Total liabilities	$53.2M	$64.5M
Common stock, $0.01 par value, 180,000,000 shares authorized; 108,319,783 and 106,453,818 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively	$1.1M	$1.1M
Additional paid-in capital	$1.7B	$1.7B
Accumulated other comprehensive (loss) income	-$31.0K	$66.0K
Accumulated deficit	-$1.4B	-$1.2B
Total stockholders' equity	$277.2M	$463.2M	$492.6M
Total liabilities and stockholders' equity	$330.4M	$527.7M
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	5.0M shares	5.0M shares
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	180.0M shares	180.0M shares
Common stock, shares issued (in shares)	108.3M shares	106.5M shares
Common stock, shares outstanding (in shares)	108.3M shares	106.5M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$77.6M	$163.6M
Investments	$111.4M	$208.7M
Prepaid expenses and other current assets	$3.8M	$5.8M
Total current assets	$192.7M	$378.2M
Property and equipment, net	$28.2M	$36.8M
Goodwill	$39.2M	$39.2M
Intangible assets	$25.1M	$25.1M
Restricted cash	$1.3M	$1.4M
Deposits	$482.0K	$529.0K
Operating lease right-of-use assets, net	$3.2M	$4.2M
Finance lease right-of-use asset, net	$40.2M	$42.4M
Total assets	$330.4M	$527.7M
Accounts payable and accrued expenses	$27.3M	$37.8M
Operating lease liabilities, current	$1.0M	$1.0M
Finance lease liability, current	$1.9M	$1.9M
Total current liabilities	$30.2M	$40.7M
Operating lease liabilities, non-current	$2.6M	$3.3M
Finance lease liability, non-current	$19.4M	$19.4M
Other liabilities	$1.1M	$1.1M
Total liabilities	$53.2M	$64.5M
Common stock, $0.01 par value, 180,000,000 shares authorized; 108,319,783 and 106,453,818 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively	$1.1M	$1.1M
Additional paid-in capital	$1.7B	$1.7B
Accumulated other comprehensive (loss) income	-$31.0K	$66.0K
Accumulated deficit	-$1.4B	-$1.2B
Total stockholders' equity	$277.2M	$463.2M	$492.6M
Total liabilities and stockholders' equity	$330.4M	$527.7M
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized (in shares)	5.0M shares	5.0M shares
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	180.0M shares	180.0M shares
Common stock, shares issued (in shares)	108.3M shares	106.5M shares
Common stock, shares outstanding (in shares)	108.3M shares	106.5M shares

Cash from operations⁵⁶⁷⁸⁴-$190.0M in 2025+194% since 2019

Capital spending⁵⁶⁷⁸⁴$440.0K in 2025−98% since 2019

Free cash flow⁵⁶⁷⁸⁴-$190.5M in 2025+117% since 2019

Share buybacks⁵$0 in 2021

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Net loss	-$223.1M	-$258.7M
Depreciation and amortization of property and equipment	$8.9M	$7.2M
Amortization of finance lease right of use asset	$2.2M	$2.2M
Impairment of operating lease right-of-use asset	$262.0K	$0
Stock-based compensation	$37.1M	$43.9M
Accretion of discount on investments, net	-$7.0M	-$8.1M
Change in fair value of warrant liabilities	$0	-$1.9M
Prepaid expenses and other assets	$2.1M	-$661.0K
Accounts payable and accrued expenses	-$10.4M	$6.1M
Operating lease liabilities and right of use assets, net	$45.0K	$89.0K
Finance lease liability	$35.0K	$95.0K
Other liabilities	-$81.0K	$81.0K
Net cash used in operating activities	-$190.0M	-$209.7M
Purchases of investments	-$276.6M	-$245.9M
Proceeds from maturities of investments	$380.8M	$383.5M
Purchases of property and equipment	-$440.0K	-$5.9M
Net cash provided by investing activities	$103.8M	$131.7M
Issuance of common stock pursuant to exercise of stock options	$0	$3.2M
Return of related party short-swing profits	$215.0K	$0
Repurchase of restricted stock units to satisfy tax withholding	-$67.0K	$0
Net cash provided by financing activities	$148.0K	$185.7M
Net change in cash, cash equivalents and restricted cash	-$86.1M	$107.7M
Accrued purchases of property and equipment, ending balance	$0	$185.0K
Receivables from sale of property and equipment, ending balance	$0	$135.0K
Operating lease liabilities	$0	$1.1M
Operating lease right of use assets	$0	$1.1M
Net unrealized loss on investments	-$97.0K	-$253.0K

Compare Rocket Pharmaceuticals Inc. with another company

Leadership

Who has led Rocket Pharmaceuticals Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

Kinnari Patel2018–2021

20202025

Chief executive officerGaurav Shah Feb 10, 2020 to now¹²
Chief executive officerDavid P. Southwell Jan 9, 2017 to Jan 24, 2017¹³
PresidentGaurav Shah Feb 10, 2020 to Feb 16, 2021¹²
PresidentDavid P. Southwell Jan 9, 2017 to Jan 24, 2017¹³
Chief financial officerAaron Ondrey Apr 3, 2024 to now¹⁴
Chief financial officerCarlos Garcia-Parada Jan 6, 2021 to Feb 16, 2022¹⁵
Chief operating officerKinnari Patel Jan 16, 2018 to Mar 26, 2021¹⁶

Board members and other officers (37)

Principal Accounting OfficerJoseph Manhede Jul 8, 2026 to now¹⁷
OfficerSarbani Chaudhuri Apr 22, 2025 to now¹⁸
OfficerSyed Ali-Aamir Rizvi Sep 22, 2025 to now¹⁹
Chief Medical OfficerMark Andrew White Apr 12, 2023 to Nov 4, 2024²⁰
OfficerKinnari Patel Feb 16, 2022 to now²¹
OfficerBrian Batchelder Jan 16, 2018 to Jan 16, 2018²²
OfficerGaurav Shah Jan 16, 2018 to Mar 5, 2019²³
OfficerJohn Militello Jan 31, 2018 to now²⁴
Vice President - FinanceDale Ritter Feb 17, 2015 to Sep 18, 2017²⁵
OfficerDavid P. Southwell Feb 17, 2015 to Mar 24, 2016²⁶
OfficerRudolph Baumgartner Feb 17, 2015 to Jan 24, 2017²⁷
OfficerWilliam K. McVicar Feb 19, 2015 to Mar 24, 2016²⁸
Board memberPiratip Pratumsuwan Feb 5, 2025 to now²⁹
Board memberPeter Fong Oct 3, 2025 to now³⁰
Board memberMikael Dolsten Sep 11, 2024 to now³¹
Board memberKeith Woods Dec 12, 2023 to Jun 20, 2024³²
Board memberFady Ibraham Malik Mar 11, 2022 to now³³
Board memberElisabeth Bjork Apr 22, 2020 to now³⁴
Board memberGaurav Shah Jan 16, 2018 to now²³
Board memberGotham Makker Jan 16, 2018 to now³⁵
Board memberNaveen Yalamanchi Jan 16, 2018 to Jun 20, 2024³⁶
Board memberPedro P. Granadillo Jan 16, 2018 to now³⁷
Board memberRoderick Wong Jan 16, 2018 to now³⁶
Board memberCarsten Boess Jan 12, 2016 to now³⁸
Board memberJ. Martin Carroll Apr 4, 2016 to Jun 21, 2017³⁹
Board memberClarence Patrick Machado Aug 18, 2016 to Jun 21, 2017⁴⁰
Board memberTimothy J. Barberich Sep 29, 2016 to Jun 21, 2017⁴¹
Board memberArgeris N. Karabelas Feb 17, 2015 to Jun 26, 2015⁴²
Board memberDevang Kantesaria Feb 17, 2015 to Feb 18, 2015⁴³
Board memberIsai Peimer Feb 17, 2015 to Jun 26, 2015⁴⁴
Board memberIttai Harel Feb 17, 2015 to Jun 26, 2015⁴⁵
Board memberMartin Vogelbaum Feb 17, 2015 to Jun 26, 2015⁴⁶
Board memberPaul G. Howes Feb 18, 2015 to Jun 21, 2017⁴⁷
Board memberDavid P. Southwell Jun 26, 2015 to now⁴⁸
Board memberRichard N. Spivey Jul 20, 2015 to Jun 21, 2017⁴⁹
Board memberGary M. Phillips Oct 13, 2015 to Jun 21, 2017⁵⁰
General counselMartin Wilson Dec 8, 2021 to now⁵¹

Former names

INOTEK PHARMACEUTICALS CORPFeb 25, 2004 to Dec 22, 2017³

Timeline

Feb 10, 2020New chief executive Gaurav Shah becomes CEO¹²
Jan 9, 2017New chief executive David P. Southwell becomes CEO¹³

Filings

518 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 71 major events, 235 insider forms, 31 large holders, 161 other. The latest 20:

Oct 6, 20268-K EDGAR
Sep 15, 2026144 EDGAR
Sep 15, 20264 EDGAR
Sep 15, 20268-K EDGAR
Sep 14, 2026144 EDGAR
Sep 11, 2026144 EDGAR
Sep 11, 2026144 EDGAR
Sep 2, 202625-NSE EDGAR
Aug 27, 20268-K EDGAR
Aug 20, 20264 EDGAR
Aug 20, 20264 EDGAR
Aug 18, 2026144 EDGAR
Aug 18, 2026144 EDGAR
Aug 18, 2026144 EDGAR
Aug 17, 20264 EDGAR
Aug 17, 20264 EDGAR
Aug 13, 2026144 EDGAR
Aug 13, 2026144 EDGAR
Aug 13, 20264 EDGAR
Aug 13, 20264 EDGAR

The 518 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 31 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Rtw Investments, LP	17,687,772	$60.5M	0.5%	No change
BlackRock, Inc.	9,923,962	$33.9M	0.0%	+2,089,167
Vanguard Portfolio Management LLC	5,810,033	$19.9M	0.0%	+1,119,818
Citigroup Inc	4,865,551	$16.6M	0.0%	−242,157
Marshall Wace, Llp	4,029,262	$13.8M	0.0%	+990,547
Millennium Management LLC	4,000,344	$13.7M	0.0%	+882,220
Newtyn Management, LLC	4,000,000	$13.7M	1.7%	+834,100
Maverick Capital Ltd	3,923,963	$13.4M	0.1%	+356,591
Vanguard Capital Management LLC	3,784,387	$12.9M	0.0%	+8,651
Aqr Capital Management LLC	3,386,162	$11.6M	0.0%	+316,232
Goldman Sachs Group Inc	2,833,427	$9.7M	0.0%	+1,112,311
Monaco Asset Management SAM	2,480,468	$8.5M	3.2%	+422,165
Geode Capital Management, LLC	2,370,729	$8.1M	0.0%	+181,473
Federated Hermes, Inc.	2,304,207	$7.9M	0.0%	+1,280,460
Jacobs Levy Equity Management, Inc	1,974,896	$6.8M	0.0%	+1,558,363
Jpmorgan Chase & Co	1,988,413	$6.7M	0.0%	+1,192,189
State Street Corp	1,820,121	$6.2M	0.0%	−2,665,868
Dimensional Fund Advisors LP	1,125,500	$3.8M	0.0%	+837,236
Morgan Stanley	1,062,522	$3.6M	0.0%	−957,586
Opaleye Management Inc.	1,000,000	$3.4M	0.3%	+45,000
D. E. Shaw & Co., Inc.	950,552	$3.3M	0.0%	−1,219,073
Jump Financial, LLC	867,900	$3.0M	0.0%	+391,422
Renaissance Technologies LLC	792,974	$2.7M	0.0%	+155,800
Charles Schwab Investment Management Inc	749,073	$2.6M	0.0%	+24,681
Northern Trust Corp	735,090	$2.5M	0.0%	+94,250

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataRocket Pharmaceuticals Inc. on Wikidata
2
SEC EDGARRocket Pharmaceuticals Inc. filings on SEC EDGAR
3
SEC EDGARRocket Pharmaceuticals Inc. filings on SEC EDGAR
4
SEC EDGARRocket Pharmaceuticals Inc. 10-K for fiscal 2025
5
SEC EDGARRocket Pharmaceuticals Inc. 10-K for fiscal 2019
6
SEC EDGARRocket Pharmaceuticals Inc. 10-K for fiscal 2020
7
SEC EDGARRocket Pharmaceuticals Inc. 10-K for fiscal 2021
8
SEC EDGARRocket Pharmaceuticals Inc. 10-K for fiscal 2022
9
SEC EDGARRocket Pharmaceuticals Inc. 10-Q for fiscal 2026
10
SEC EDGARRocket Pharmaceuticals Inc. 10-Q for fiscal 2026
11
SEC EDGARRocket Pharmaceuticals Inc. 10-K for fiscal 2019
12
SEC EDGARGaurav Shah, Chief executive officer
13
SEC EDGARDavid P. Southwell, Chief executive officer
14
SEC EDGARAaron Ondrey, Chief financial officer
15
SEC EDGARCarlos Garcia-Parada, Chief financial officer
16
SEC EDGARKinnari Patel, Chief operating officer
17
SEC EDGARJoseph Manhede, Principal Accounting Officer
18
SEC EDGARSarbani Chaudhuri, Officer
19
SEC EDGARSyed Ali-Aamir Rizvi, Officer
20
SEC EDGARMark Andrew White, Chief Medical Officer
21
SEC EDGARKinnari Patel, Officer
22
SEC EDGARBrian Batchelder, Officer
23
SEC EDGARGaurav Shah, Officer
24
SEC EDGARJohn Militello, Officer
25
SEC EDGARDale Ritter, Vice President - Finance
26
SEC EDGARDavid P. Southwell, Officer
27
SEC EDGARRudolph Baumgartner, Officer
28
SEC EDGARWilliam K. McVicar, Officer
29
SEC EDGARPiratip Pratumsuwan, Board member
30
SEC EDGARPeter Fong, Board member
31
SEC EDGARMikael Dolsten, Board member
32
SEC EDGARKeith Woods, Board member
33
SEC EDGARFady Ibraham Malik, Board member
34
SEC EDGARElisabeth Bjork, Board member
35
SEC EDGARGotham Makker, Board member
36
SEC EDGARNaveen Yalamanchi, Board member
37
SEC EDGARPedro P. Granadillo, Board member
38
SEC EDGARCarsten Boess, Board member
39
SEC EDGARJ. Martin Carroll, Board member
40
SEC EDGARClarence Patrick Machado, Board member
41
SEC EDGARTimothy J. Barberich, Board member
42
SEC EDGARArgeris N. Karabelas, Board member
43
SEC EDGARDevang Kantesaria, Board member
44
SEC EDGARIsai Peimer, Board member
45
SEC EDGARIttai Harel, Board member
46
SEC EDGARMartin Vogelbaum, Board member
47
SEC EDGARPaul G. Howes, Board member
48
SEC EDGARDavid P. Southwell, Board member
49
SEC EDGARRichard N. Spivey, Board member
50
SEC EDGARGary M. Phillips, Board member
51
SEC EDGARMartin Wilson, General counsel